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De novo LINE-1 (long interspersed element–1, or L1) retrotransposition events are responsible for ∼1/1,000 disease-
causing mutations in humans. Previously, L1.2 was identified as the likely progenitor of a mutagenic insertion in
the factor VIII gene in a patient with hemophilia A. It subsequently was shown to be one of a small number of
active L1s in the human genome. Here, we demonstrate that L1.2 is present at an intermediate insertion allele
frequency in worldwide human populations and that common alleles (L1.2A and L1.2B) exhibit an ∼16-fold
difference in their ability to retrotranspose in cultured human HeLa cells. Chimera analysis revealed that two amino
acid substitutions (S1259L and I1220M) downstream of the conserved cysteine-rich motif in L1 open reading frame
2 are largely responsible for the observed reduction in L1.2A retrotransposition efficiency. Thus, common L1 alleles
can vary widely in their retrotransposition potential. We propose that such allelic heterogeneity can influence the
potential L1 mutational load present in an individual genome.
LINE-1 (long interspersed element–1, or L1) is an abun-
dant family of non–long terminal repeat retrotranspo-
sons that comprises ∼17% of human DNA (Smit 1996;
Lander et al. 2001). The vast majority (199.8%) of L1s
can no longer retrotranspose because they are 5′ trun-
cated, internally rearranged, or mutated (reviewed by
Moran and Gilbert 2002). However, the average human
genome is estimated to contain ∼60–100 retrotranspo-
sition-competent L1s (RC-L1s), and ∼10% of these el-
ements are classified as highly active, or “hot” (Sassaman
et al. 1997; Brouha et al. 2003). The majority of RC-
L1s are members of the Ta (Transcribed active) subfam-
ily (Skowronski et al. 1988), and many are polymorphic
with respect to presence, indicating that they have ret-
rotransposed since the origin of our species (Boissinot
et al. 2000; Sheen et al. 2000; Ovchinnikov et al. 2001;
Myers et al. 2002).
A consensus RC-L1 is ∼6 kb in length and contains
a 5′ UTR, two nonoverlapping ORFs (ORF1 and ORF2),
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and a 3′ UTR that ends in a poly (A) tail (fig. 1B) (Scott
et al. 1987; Dombroski et al. 1991; Moran and Gilbert
2002; Brouha et al. 2003). ORF1 encodes a 40-kDa
nucleic acid–binding protein (Holmes et al. 1992; Hoh-
joh and Singer 1996, 1997). ORF2 encodes a protein
with both endonuclease (EN) and reverse transcriptase
(RT) activities that also contains a cysteine-rich motif
(CX3CX7HX4C) of unknown function (Fanning and
Singer 1987; Mathias et al. 1991; Feng et al. 1996). Both
proteins are required for retrotransposition (Moran et
al. 1996), which likely occurs by a mechanism termed
“target site–primed reverse transcription” (TPRT) (Luan
et al. 1993; Luan and Eickbush 1995; Feng et al. 1996).
RC-L1 retrotransposition continues to impact the hu-
man genome. For example, 14 disease-producing de novo
L1 retrotransposition events have been identified in hu-
mans (reviewed by Ostertag and Kazazian 2001). RC-L1s
also can mobilize sequences derived from both their 5′
and 3′ flanks in cis by a process termed “L1-mediated
transduction” (Holmes et al. 1994; Moran et al. 1999;
Goodier et al. 2000; Pickeral et al. 2000; Lander et al.
2001). Finally, the RC-L1 encoded proteins also may
function in trans, resulting in the mobilization of Alu
elements and the formation of processed pseudogenes,
which together comprise ∼10% of genomic DNA (Boeke
1997; Esnault et al. 2000; Wei et al. 2001; Dewannieux
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Figure 1 LRE-1 locus and sequence differences between L1.2A, L1.2B, and L1.3. A, The LRE-1 locus has both unoccupied and L1.2
inserted alleles. L1.2 is flanked by 15-bp target site duplications (bold black horizontal arrows) (Dombroski et al. 1991). The positions of the
diagnostic restriction sites (P p PstI, B p BamHI, and R p EcoRI) were inferred from the available sequence of the unoccupied (GenBank
accession number D87016) and inserted alleles (Dombroski et al. 1991). The thick black line represents the EcoRI probe used in Southern blot
analysis by Dombroski et al. (1991). The sizes of the PstI restriction fragments detected from the unoccupied and inserted alleles are indicated
under the brackets and would not have been differentiated in the previous analysis (Dombroski et al. 1991). The relative positions of the primers
(FWD, REV, Ta, and JH-27) used to determine both the inserted allele frequency and the allele frequencies of L1.2A and L1.2B are designated
by gray horizontal arrows. B, A schematic of a full-length RC-L1. The EN and RT domains and the cysteine-rich motif of ORF2 are indicated.
Thick vertical lines within the L1 schematic denote the relative positions of sequence differences between the three L1s. Diagnostic DNA and
amino acid sequences peculiar to L1.2A, L1.2B, and L1.3 are shown below the schematic. Thick black and gray lines indicate nucleotide
differences, whereas black and gray squares denote amino acid sequence differences. Black lines and squares indicate that the designated
nucleotide and amino acid match the consensus sequence of a “hot” L1 (Brouha et al. 2003). Gray lines and squares indicate deviations from
the consensus sequence. The amino acid numbering convention is based on the sequence of L1.2 (Dombroski et al. 1991). G p glycine; R p
arginine; Q p glutamine; M p methionine; I p isoleucine; L p leucine; S p serine. The approximate locations of the restriction sites used
to construct the chimeric L1s are shown. For example, JM101L1.2A (M1220I) was created by replacing the 0.25-kb SpeI-NcoI restriction
fragment from pJCC48/L1.2A with an analogous fragment from pJCC48/L1.3 (Moran et al. 1996). The 8.1-kb NotI-BstZ17I restriction fragment
from the resultant construct then was used to replace the corresponding fragment in JM101L1.3 (Sassaman et al. 1997; Wei et al. 2001). Similar
strategies were employed to make the other chimeric constructs noted in tables 4 and 5.
et al. 2003; Ejima and Yang 2003). Thus, either directly
or through the promiscuous mobilization of cellular
RNAs, L1 retrotransposition continues to shape the
genome.
L1.2 was identified as the likely progenitor of a mu-
tagenic insertion into the factor VIII gene in a patient
with hemophilia A (Kazazian et al. 1988; Dombroski
et al. 1991). It is a member of the Ta subfamily and
resides at a locus designated “LRE-1” on chromosome
22q11.22 (fig. 1A). The initial characterization of L1.2
identified at least two alleles, L1.2A and L1.2B. L1.2A
was isolated from a commercial genomic library, and
L1.2B was isolated from the mother of the patient. These
two elements differ at only 3 nt positions in ORF2 (fig.
1B) (Dombroski et al. 1991).
Previous Southern blot data indicated that L1.2 might
be fixed with respect to presence in human DNA (Dom-
broski et al. 1991). However, we were able to identify
only the unoccupied allele of LRE-1 in the human ge-
nome working draft sequence (HGWD), indicating that
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Table 1
Insertion Allele Frequency of L1.2 at Locus LRE1
POPULATIONa
SAMPLE
(n)b
INSERTION
()
FREQUENCYc
NO. OF INDIVIDUALS
WITH GENOTYPEd
UNBIASED
HETEROZYGOSITY /   /   / 
African Americans 20 .325 0 13 7 .45
Alaskan natives 20 .5 4 12 4 .513
German European 20 .4 3 10 7 .492
South Americans 20 .475 4 11 5 .512
Average .425 .492
Additional population 365 .374 59 155 151 .469
a Populations of individual DNAs used in this study.
b Number of individual DNA samples tested for L1.2.
c Insertion () frequency of L1.2.
d Empty alleles are denoted with a (). / and / indicate individuals who are homozygous
for presence/absence, respectively. / indicates heterozygous individuals. Exact tests using a Mar-
kov chain (Guo and Thompson 1992) were used to test for HWE. When a 1% CI was used, none
of the populations deviated significantly from HWE.
Table 2
L1.2A/L1.2B Allele Frequency Determination: Actual Number of Individuals Sequenced, by
Genotype
POPULATION
NO. OF
NO. OF INDIVIDUALS
SEQUENCED FREQUENCY OF
 Alleles
Sequenced
L1.2 A
Alleles
L1.2 B
Alleles A/A A/B A/ B/ L1.2A L1.2B
African Americans 8 3 5 0 0 3 5 .375 .625
Alaskan natives 12 11 1 2 0 7 1 .917 .083
German European 10 5 5 0 0 5 5 .5 .5
South Americans 15 11 4 2 1 6 3 .733 .267
Total/average 45 30 15 4 1 21 14 .667 .333
NOTE.—Allele frequencies were determined as in table 1. Details regarding the ascertainment of
alleles are provided in the text.
L1.2 may be polymorphic with respect to presence. In-
deed, examination of the HGWD indicated that the pre-
vious Southern blot analyses could not differentiate be-
tween occupied (i.e., inserted) and unoccupied (i.e.,
empty) alleles of LRE-1, because the PstI restriction frag-
ment in both alleles is similar in size (fig. 1A).
To determine the inserted allele frequency of L1.2, we
used a previously developed PCR-based strategy (Sheen
et al. 2000; Ovchinnikov et al. 2001; Myers et al. 2002)
to assess the presence/absence status of L1.2 in a panel
of 80 DNA samples isolated from 20 individuals of Af-
rican American, Alaskan native, European, or South
American descent (fig. 1A). These data then were used
to calculate the L1.2 insertion frequency and heterozy-
gosity values for each population group, as well as the
average values across all four populations. The average
L1.2 insertion frequency across all populations is 0.425,
and the average unbiased heterozygosity is 0.492 (table
1). We next extended our analysis to include an addi-
tional 365 individuals of unknown ethnic/racial origin.
For these 365 individuals, the L1.2 insertion frequency
is 0.374, and the unbiased heterozygosity value is 0.469
(table 1). Thus, our data indicate that L1.2 is present at
an intermediate insertion frequency in the human pop-
ulation, consistent with the human-specific origin of
the L1 Ta subfamily (Boissinot et al. 2000; Sheen et al.
2000).
To assess the respective allele frequencies of L1.2A
and B, we used primers JH27 and REV to amplify the
LRE-1 locus from 57 individuals who were either het-
erozygous (/; 46 individuals) or homozygous (/;
11 individuals) for the insertion (fig. 1A). The resultant
PCR products were cloned, and 45 of 68 PCR products
yielded high-quality DNA sequence. Diagnostic nucle-
otides then were used to differentiate L1.2A from L1.2B
(fig. 1B; table 2). The allele frequency of L1.2A in these
samples is 0.667, whereas that of L1.2B is 0.333. Since
the average L1.2 insertion frequency is 0.425 (see table
1 and above), we calculate the overall allele frequencies
for L1.2A and L1.2B as 0.283 and 0.142, respectively
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Table 3
L1.2A/ L1.2B Allele Frequency Determination: Predicted Number of Individuals with Given
Genotypes if All Individuals Were Sequenced
POPULATION
PREDICTED NO. OF INDIVIDUALS WITH GENOTYPE
OVERALL
FREQUENCY OF
A/A A/B B/B A/ B/  /  L1.2A L1.2B ()
African Americans 0 0 0 4.875 8.125 7 .122 .203 .325
Alaskan natives 3.682 .304 .014 10.668 1.332 4 .459 .042 .5
German European .75 1.5 .75 5 5 7 .2 .2 .4
South Americans 2.537 1.391 .071 7.466 3.534 5 .348 .127 .475
Total/average 6.669 3.665 .665 28.337 17.663 23 .283 .142 .425
NOTE.—Allele frequencies were determined as in table 1. Details regarding the ascertainment of alleles
are provided in the text.
Table 4
Results of the Cultured Cell Retrotransposition Assay: JM101/L1.2A, JM101/L1.2B, and Associated Chimeras
CONSTRUCT
MEAN NO. OF COLONIES PER WELL  SD % OF JM101/L1.2B
Trial 1
( )np 3
Trial 2
( )np 3
Trial 3
( )np 9
Trial 4
( )np 9
Trial 1
( )np 3
Trial 2
( )np 3
Trial 3
( )np 9
Trial 4
( )np 9
Average
of Trials
JM101/L1.2B 142  16 49  4.7 60  6.7 78  12 100 100 100 100 100
JM101/L1.2A (M1220I/L1259S) 132  11 49  3.5 55  6.7 67  12 93 100 92 86 93
JM101/L1.2A (L1259S) 86  11 57  4.0 56  9.8 64  11 61 116 93 93 91
JM101/L1.2A (M1220I) 21  1.5 13  4.7 17  3.2 29  2.3 15 27 28 37 27
JM101/L1.2A 8  1.7 2  1.0 4  2.2 5  1.5 6 4 7 6 6
JM105/L1.3 0 .7  1.2 .1  .3 .2  .7 0 !.01 0 !.01 !.01
NOTE.—The constructs in tables 4 and 5 were tested in the same trial (i.e., trial 1 p trial 1 in the two tables). Cells were plated in six-well
dishes at 5#103 cells/well in all trials except trial 2, in which they were plated at 2#103 cells/well. In each trial, .5 mg of each construct was
cotransfected with an equal amount of hrGFP (Stratagene). n p the number of wells scored in each trial. Transfection efficiencies for each
construct were determined by flow cytometry (Wei et al. 2000). The proportion of cells expressing GFP averaged 81% and was similar for
each of the tested constructs. The number of G418-resistant foci and the standard deviation for each trial is reported. JM105/L1.3 contains a
missense mutation in the RT active site and serves as a negative control (Wei et al. 2001).
(table 3). These values are in general agreement with
previously published data (Dombroski et al. 1991). Al-
though we characterized only a relatively small number
of individual L1.2 alleles, our data also suggest that the
L1.2A and L1.2B allele frequencies may differ among
population groups.
We recently determined that L1.2B is a “hot” L1
(Brouha et al. 2003), and we demonstrate here that it
can retrotranspose at a ∼16-fold higher efficiency than
L1.2A in cultured human HeLa cells (table 4). Two of
three nucleotide differences between L1.2A and L1.2B
result in amino acid changes (I1220M and S1259L)
downstream of the conserved cysteine-rich motif
(CX3CX7HX4C) of L1 ORF2 (fig. 1B). It is notable that
the amino acid substitutions in L1.2A (M1220 and
L1259) deviate from the consensus sequence of a “hot”
L1 (Brouha et al. 2003). To determine the amino acid(s)
responsible for the observed difference in retrotrans-
position efficiency, we took advantage of unique restric-
tion sites within the L1 sequence to generate L1.2A/
L1.2B chimeras (fig. 1B). These chimeras then were
tested for their ability to retrotranspose in the transient
retrotransposition assay (table 4) (Wei et al. 2000). It is
interesting that we found that S1259L is responsible for
∼80% of the difference in retrotransposition activity be-
tween L1.2A and L1.2B. By comparison, I1220M affects
retrotransposition to a lesser extent, accounting for
∼20% of the difference.
L1.2A and L1.2B also share two other amino acid
substitutions that deviate from the consensus sequence
of a “hot” L1 (Brouha et al. 2003). The first substitution,
R363G, is located between the L1 ORF2 EN and RT
domains, in a putative Myb-like domain (Kubo et al.
2001); the second substitution, Q689R, is located in the
L1 RT domain. We hypothesized that these substitutions
may affect retrotransposition efficiency, since L1.3, a
previously characterized RC-L1 that matches the hot L1
consensus at these positions, retrotransposes in HeLa
cells at ∼10–20-fold higher efficiencies than L1.2A
(Dombroski et al. 1991, 1993; Sassaman et al. 1997;
Wei et al. 2000). To examine the effect of these substi-
tutions on retrotransposition, we created L1.2A/L1.3
chimeras and assayed each of the resultant constructs
for their ability to retrotranspose (fig. 1B; table 5). Con-
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Table 5
Results of the Cultured Cell Retrotransposition Assay: JM101/L1.2A, JM101/L1.3, and Associated Chimeras
CONSTRUCT
MEAN NO. OF COLONIES
PER WELL  SD % OF JM101/L1.3
Trial 1
( )np 3
Trial 2
( )np 3
Trial 3
( )np 9
Trial 1
( )np 3
Trial 2
( )np 3
Trial 3
( )np 9
Average
of Trials
JM101/L1.3 202  35 71  1.5 77  6.4 100 100 100 100
JM101/L1.3 (Q689R) 199  36 65  5.0 77  17 99 92 100 97
JM101/L1.3 (R363G) 148  14 67  5.2 65  13 73 94 84 84
JM101/L1.3 (I1220M) 124  15 54  3.5 64  7.5 61 76 83 73
JM101/L1.3 (S1259L) 28  5.6 19  5.0 23  4.1 14 27 30 24
JM101/L1.2A (G363R) 10  1.0 5  .6 10  3.6 5 7 13 8
JM101/L1.3 (I1220M/S1259L) 12  4.0 3  1.5 7  3.2 6 4 9 6
JM101/L1.2A 8  1.7 2  1.0 4  2.2 4 3 5 4
JM105/L1.3 0 .7  1.2 .1  .3 0 !.01 !.01 !.01
NOTE.—The constructs in tables 4 and 5 were tested in the same trial (i.e., trial 1 p trial 1 in the two tables).
Cells were plated in six-well dishes at 5#103 cells/well in all trials except trial 2, in which they were plated at 2#103
cells/well. In each trial, .5 mg of each construct was cotransfected with an equal amount of hrGFP (Stratagene). np
the number of wells scored in each trial. Transfection efficiencies for each construct were determined by flow cytometry
(Wei et al. 2000). The proportion of cells expressing GFP averaged 81% and was similar for each of the tested
constructs. The number of G418-resistant foci and the standard deviation for each trial is reported. JM105/L1.3
contains a missense mutation in the RT active site and serves as a negative control (Wei et al. 2001).
sistent with the above analysis, our data indicate that
I1220M and S1259L are largely responsible for the dif-
ference in retrotransposition activity between L1.2A and
L1.3. By comparison, R363G is responsible for only
!10% of the difference in retrotransposition, whereas
Q689R had virtually no effect on retrotransposition (ta-
bles 4 and 5).
In sum, we have determined that L1.2 is present at
an intermediate insertion frequency in various popula-
tion groups and have demonstrated that common alleles
(L1.2A and L1.2B) exhibit a ∼16-fold difference in their
ability to retrotranspose in cultured human HeLa cells.
Chimera analysis revealed that two amino acid substi-
tutions (I1220M and S1259L) downstream of the con-
served cysteine-rich motif (CX3CX7HX4C) in L1 ORF2
likely are responsible for the observed reduction in
L1.2A retrotransposition efficiency. Interestingly, S1259
also is conserved in the canine ORF2-encoded protein
(Choi et al. 1999), although it is encoded by a different
codon (UCG in human vs. AGU in canine). Similarly,
threonine, another nucleophilic amino acid, is present
in the active mouse consensus and rat ORF2-encoded
proteins. Thus, our data suggest that the amino acid
difference (S1259L), and not nucleotide changes that
adversely affect L1 RNA, causes most of the observed
reduction in L1.2A retrotransposition efficiency.
Future studies are needed to determine how amino
acid substitutions downstream of the conserved cysteine-
rich motif adversely affect L1 retrotransposition. Prelim-
inary data indicate that retrotransposed sequences de-
rived from L1.3 and L1.2A in cultured human cells are
similar in structure and commonly are 5′ truncated
(Moran et al. 1996; Gilbert et al. 2002). Thus, it is likely
that I1220M and S1259L directly affect retrotranspo-
sition efficiency, perhaps by altering template binding,
ribonucleoprotein particle transport, and/or initial steps
in TPRT. However, it is possible that some of the dif-
ference in retrotransposition efficiency we observe re-
flects the ability of L1.3 and L1.2B to retrotranspose 1.6
kb of sequence (i.e., the length of retrotransposed cDNA
required to confer G418-resistance to cells) more effi-
ciently than L1.2A.
Our data suggest that, besides presence/absence di-
morphism, allelic heterogeneity also can contribute to
differences in L1 retrotransposition potential. For ex-
ample, if an L1 is polymorphic with respect to pres-
ence—and, when present, has two possible alleles (A and
B) that differ in their ability to retrotranspose (i.e., Ap
1# vs. B p 16# retrotransposition efficiencies)—then
any individual in the population may have one of the
following six possible genotypes at that specific locus:
B16#/B16#, B16#/A1#, B16#/, A1#/A1#,
A1#/, or /. On the basis of our calculated allele
frequencies, we would predict that a person of genotype
B16#/B16# has the greatest probability of obtaining
a new retrotransposition event, with the probability de-
creasing in the following genotypic order: B16#/B16#
(2% of individuals) 1 B16#/A1# (8% of individuals)
1 B16#/ (16% of individuals) 1 A1#/A1# (8% of
individuals) 1 A1#/ (33% of individuals) 1/ (33%
of individuals). Similarly, three L1 alleles with different
retrotransposition activities would produce 10 potential
genotypes, and so on. Indeed, our data predict that both
presence/absence dimorphism and L1 allelic heteroge-
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neity could, in principle, influence the L1 mutational
load present in an individual’s genome.
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